Arrowhead’s ARO-APOC3 an Orphan Drug in U.S. for FCS

The FDA has granted orphan drug designation to Arrowhead Pharmaceuticals’ (NASDAQ:ARWR) ARO-APOC3 for the treatment of familial chylomicronemia syndrome (FCS).

Currently no therapy is available in U.S. that can adequately treat FCS.

Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

https://seekingalpha.com/news/3472921-arrowheads-aro-apoc3-orphan-drug-u-s-fcs